Clinical update on the SHELTER study: A phase I/II trial of the HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC). A phase II study of capecitabine in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback